600 patients67,035 observations120 daysLIVE

Patient P-01479

Synthetic patientNBL-101 · Day 114 · 75+ · F · baseline S03Steering view · 3DOpen companion preview
Is the drug working?

Therapy response 75 at the day-84 endpoint (observed).

Why responding?

Responding: response probability 79%, therapy response 80 today; biology is not blocking the drug.

Is a side effect starting?

Drift detected on day 17 (HRV −9 ms, resting HR +5 bpm, sleep −2.1 h, gi toxicity +36, inflammatory load +34); the side effect would have been reported on day 20 — 3 days of warning.

Still taking it?

8 of 9 scheduled doses in the last 60 days are biologically confirmed (89%); 1 were logged but show no dose signature. Dose signature: resting HR +7 bpm, HRV −6 ms.

last 9 doses · green confirmed · amber logged only · red missed
Plan for this patient
stable, no actionrecommendowner · Companionreview day 121Human Model →
Next action
No action indicated; maintain.
Kept if

Trajectory is stable relative to similar patients; keep the current content.

Daily to-dos in the companion
  • 🍽Keep meals regular; three to four moderate portions spaced through the day
  • 🍽Include a cooked vegetable portion with each main meal
  • Log the daily check-in; one line is enough
  • Keep the current walking rhythm
  • 💊Take the scheduled dose as agreed with your care team
  • 💊No additional supplements this week
Adherence
97% stable

Adherence is not the problem.

Changes the plan if

sleep quality falling under 35 while GI rises

LLIFE OS insight
grounded · add an LLM key for prose

P-01479 is on day 114 of NBL-101 (EC-02, baseline S03): response favorable, tolerance favorable, GI deteriorating. Over 14 days response moved +1 and GI +5; discontinuation risk is 27%. The state is in the restoration basin, heading towards failing, after diverging from the model on day 17.

Butyrate capacity 60/100, diversity 3.5, rapid metabolizer. Pushing it down: Escherichia coli 9.78% (LPS load) (-25.8), Rapid metabolizer (-12.7), Poor-sleep week (-3). Pulling it up: Butyrate producers intact (+11.9).

No action has been tried yet.

No action is indicated now; the trajectory is stable relative to similar patients.

Therapy response
Favorable
Tolerance
Favorable
GI state
Deteriorating
Inflammatory state
Deteriorating
Nutritional resilience
Stable
Discontinuation risk
27%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events
solid = observed · dashed = predicted · dose (weekly infusion, day 1 of each 7-day cycle)
  1. Day 0 NBL-101 startedBaseline state S03
  2. Day 17 Trajectory diverged from predictionObserved response fell below the model's expected path.

What changed?

Trajectory began diverging from predicted response on Day 17.

Primary contributors, last 14 days
  • GI instability+5
  • Inflammatory activity+4
  • Toxicity+4
  • Treatment adherence+3

What helped?

No interventions yet.

    LIFE OS recommendation
    No intervention is indicated right now. The trajectory is stable relative to similar patients. See what worked for similar patients.

    Daily trackers

    Asset settings

    The trackers this program marks as important, last 14 days vs the 14 before.

    GI burden
    Companion
    33/100
    worsening · +8.1 vs previous 14 d
    Toxicity
    Blood
    19.5/100
    improving · -2.0 vs previous 14 d
    Sleep quality
    Wearable
    43.3/100
    worsening · -10.4 vs previous 14 d
    Energy level
    Daily log
    5.6/10
    worsening · -0.4 vs previous 14 d
    Stress level
    Daily log
    3.7/10
    worsening · +0.2 vs previous 14 d
    Steps
    Wearable
    7,724
    stable · -137 vs previous 14 d
    Adherence
    Companion
    96.6 %
    stable · -0.4 vs previous 14 d
    This trajectory is decaying — what would help, what would not
    Steering view →

    Heading towards failing · 74 from the failing basin, 19 from restoration.

    Would help
    • No untried action with strong evidence. Compose one from primitives.
    Would not help
    • Nothing clearly counter-productive in the record.
    State influencers · digestive

    Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

    • Histamine load
      -1.6no signal · 31%
    • Insoluble fibre
      +1.4no signal · 31%
    • Dietary fat load
      -1no signal · 23%
    • Simple carbohydrates
      +0.9no signal · 16%
    • Alcohol
      +0.9no signal · 22%
    • Spicy / capsaicin
      -0.6no signal · 15%

    DeepGene damage signature

    The metagenomic + host-DNA read-out that initializes this patient's biology and, on retest, measures whether the steering worked.

    Damage score · retest day 90
    32/100
    vs baseline (day 0)
    +1
    2 improved · 3 worsened
    synthetic signature · consistent with this patient's biology
    • 3 opportunists above range: Escherichia coli, Enterococcus faecium, Clostridioides difficile
    • 2 keystone species absent
    • 3 resistance genes
    Pathogens / opportunists3/5
    from 2
    Keystone species2/8
    from 1
    Diversity0/2
    from 1
    Metabolic modules0/4
    Vitamin synthesis1/7
    Oral translocation1/1
    Host DNA0/1
    Tissue recycling0/1
    Central mechanisms0/2
    Virulence factors2/2
    from 1
    Antibiotic resistance genes3/3
    from 4
    Genetic predisposition2/2
    Opportunists above range
    Escherichia coli 9.78% AR
    Enterococcus faecium 4.89% AR
    Clostridioides difficile 0.978% AR
    Keystone species absent
    Akkermansia muciniphila, Bifidobacterium longum
    Capacity
    Shannon 3.1 · butyrate 789 CPM · SCFA 1188
    1 vitamins below
    Host & mechanisms
    tissue recycling 30/100
    oral translocation 2.25% AR
    3 resistance genes · 2 virulence factors

    Biological layers

    Which pathways look influenced, and by which layer of this person's biology.

    Pathways under pressure
    • Drug metabolism and exposure 35
      • DNADPYD *2A → slower clearance
    • Mucosal barrier integrity 30
      • MicrobiomeAkkermansia low → thinner mucus layer
    • Butyrate / short-chain fatty acid production 25
      • MicrobiomeF. prausnitzii depleted
    • Autonomic recovery 25
      • WearableResting HR 79 bpm
    DNA
    Fictional pharmacogenomic panel
    • DPYD *2A heterozygous
      Slower drug clearance
    • CYP2D6 Rapid metabolizer
      Expected exposure
    • MTHFR C677T
      Reduced folate turnover
    Microbiome
    Shannon diversity 3.5 · butyrate capacity 60/100
    • Akkermansia muciniphilaLow
    • Faecalibacterium prausnitziiLow
    • Bacteroides fragilisNormal
    • Bifidobacterium longumLow
    • EnterobacteriaceaeNormal
    Wearable, last 14 days
    daily evolution fed into the runtime
    HRV
    64 ms
    Sleep
    6.3 h
    Steps
    9,063
    Resting HR
    76 bpm
    Daily log: GI score 33, nutritional resilience 57, adherence 97.

    What this patient sees in NostraAI

    The content that steers the trajectory: what to eat, what to do, what to take.

    Open companion preview
    What to eat
    • Keep meals regular; three to four moderate portions spaced through the day
    • Include a cooked vegetable portion with each main meal
    • Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
    • Avoid known triggers for now: fried or oily food, dairy, alcohol
    What to do
    • Log the daily check-in; one line is enough
    • Keep the current walking rhythm
    • Keep the sleep window steady
    • Keep hydration steady: small amounts through the day rather than large volumes at once
    What to take
    • Take the scheduled dose as agreed with your care team
    • No additional supplements this week
    • Fictional demo item: continue vitamin D as before

    284 biologically similar trajectories

    Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

    PatientSimilarityBaselineInterventionOutcomeResponse today
    P-0185546%S18GI-04improved76
    P-0166445%S07CR-01improved85
    P-0171143%S03ME-01improved82
    P-0162641%S04GI-04improved77
    P-0189641%S06CR-01improved73
    P-0148938%S05BR-03improved83
    P-0142837%S18DT-01improved82
    P-0176637%S01BR-03improved83
    P-0152836%S20DT-01improved89
    P-0164234%S07ME-01improved59
    P-0134233%S13DT-01improved59
    P-0163833%S04GI-04improved83